Skip to main content

CORRECTION article

Front. Immunol., 22 March 2021
Sec. Vaccines and Molecular Therapeutics
Volume 12 - 2021 | https://doi.org/10.3389/fimmu.2021.671443

Corrigendum: High-Dose Intravenous Immunoglobulin in Severe Coronavirus Disease 2019: A Multicenter Retrospective Study in China

This article is a correction to:

  1. High-Dose Intravenous Immunoglobulin in Severe Coronavirus Disease 2019: A Multicenter Retrospective Study in China

    1. Read original article
Wei Cao&#x;Wei Cao1†Xiaosheng Liu,,&#x;Xiaosheng Liu1,2,3†Ke HongKe Hong4Zhiyong MaZhiyong Ma5Yuelun ZhangYuelun Zhang6Ling LinLing Lin1Yang HanYang Han1Yong XiongYong Xiong5Zhengyin LiuZhengyin Liu1Lianguo RuanLianguo Ruan4Taisheng Li,,*Taisheng Li1,2,3*
  • 1Department of Infectious Diseases, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China
  • 2Department of Basic Medical Sciences, School of Medicine, Tsinghua University, Beijing, China
  • 3Tsinghua-Peking Center for Life Sciences, Beijing, China
  • 4Department of Infectious Diseases, JinYin-tan Hospital, Wuhan, China
  • 5Department of Infectious Diseases, Zhongnan Hospital of Wuhan University, Wuhan, China
  • 6Medial Research Center, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China

A Corrigendum on
High-Dose Intravenous Immunoglobulin in Severe Coronavirus Disease 2019: A Multicenter Retrospective Study in China

By Cao W, Liu XS, Hong K, Ma ZY, Zhang YL, Lin L, et al. (2021). doi: 10.3389/fimmu.2021.627844

Error in Table

In the original article, there was a mistake in Table 1 as published. The author identified the calculating errors in the percentage of comorbidity, symptoms, and treatment. The corrected Table 1 appears below.

TABLE 1
www.frontiersin.org

Table 1 Clinical and relevant baseline characteristics of patients.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Keywords: COVID-19, high-dose intravenous immunoglobulin, immunomodulation, 28-day mortality, inflammatory markers

Citation: Cao W, Liu X, Hong K, Ma Z, Zhang Y, Lin L, Han Y, Xiong Y, Liu Z, Ruan L and Li T (2021) Corrigendum: High-Dose Intravenous Immunoglobulin in Severe Coronavirus Disease 2019: A Multicenter Retrospective Study in China. Front. Immunol. 12:671443. doi: 10.3389/fimmu.2021.671443

Received: 23 February 2021; Accepted: 04 March 2021;
Published: 22 March 2021.

Edited and reviewed by: Christoph T. Berger, University of Basel, Switzerland

Copyright © 2021 Cao, Liu, Hong, Ma, Zhang, Lin, Han, Xiong, Liu, Ruan and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Taisheng Li, bGl0c2hAMjYzLm5ldA==

†These authors have contributed equally to this work

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.